Mereo BioPharma Company Leadership
| MREO Stock | USD 3.56 0.16 4.71% |
Mereo BioPharma's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Mereo BioPharma Group suggests that virtually all insiders are panicking. Mereo BioPharma employs about 33 people. The company is managed by 12 executives with a total tenure of roughly 77 years, averaging almost 6.0 years of service per executive, having 2.75 employees per reported executive.
| Denise ScotsKnight CEO CEO, Co-Founder, Executive Director |
Mereo BioPharma's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-09-12 | John A Lewicki | Disposed 5212 @ 4.47 | View | ||
| 2024-08-22 | Deepika Pakianathan | Disposed 105244 @ 4.43 | View | ||
| 2024-06-25 | John A Lewicki | Disposed 7416 @ 3.69 | View | ||
| 2024-05-22 | Alexandra Hughes-Wilson | Disposed 100432 @ 2.97 | View |
Monitoring Mereo BioPharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Mereo |
Mereo BioPharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Mereo BioPharma's future performance. Based on our forecasts, it is anticipated that Mereo will maintain a workforce of about 30 employees by December 2024.Mereo BioPharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2386) % which means that it has lost $0.2386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4847) %, meaning that it created substantial loss on money invested by shareholders. Mereo BioPharma's management efficiency ratios could be used to measure how well Mereo BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.47. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Mereo BioPharma's Total Assets are very stable compared to the past year. As of the 28th of November 2024, Net Tangible Assets is likely to grow to about 45.6 M, while Non Current Assets Total are likely to drop about 2.6 M.As of the 28th of November 2024, Common Stock Shares Outstanding is likely to grow to about 692.4 M, while Net Loss is likely to drop (32.3 M).
Mereo BioPharma Workforce Comparison
Mereo BioPharma Group is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 563. Mereo BioPharma holds roughly 33.0 in number of employees claiming about 6% of equities under Health Care industry.
Mereo BioPharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mereo BioPharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mereo BioPharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mereo BioPharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mereo BioPharma Notable Stakeholders
A Mereo BioPharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mereo BioPharma often face trade-offs trying to please all of them. Mereo BioPharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mereo BioPharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Charles Sermon | Co-Founder, General Counsel, Secretary | Profile | |
| John MBA | CoFounder Officer | Profile | |
| Denise ScotsKnight | CEO, Co-Founder, Executive Director | Profile | |
| Christine CPA | Chief Officer | Profile | |
| Bo Kara | Senior CMC | Profile | |
| Fiona Bor | Head Property | Profile | |
| Jackie Parkin | Therapy Endocrinology | Profile | |
| MBBS MD | CoFounder Strategy | Profile | |
| John Lewicki | Chief Officer | Profile | |
| Alexandra HughesWilson | Chief Planning | Profile | |
| Suba Krishnan | Senior Development | Profile | |
| MBA MBA | CoFounder Officer | Profile |
About Mereo BioPharma Management Performance
The success or failure of an entity such as Mereo BioPharma Group often depends on how effective the management is. Mereo BioPharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mereo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mereo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.50) | (0.52) | |
| Return On Assets | (0.44) | (0.47) | |
| Return On Equity | (0.58) | (0.55) |
Mereo BioPharma Workforce Analysis
Traditionally, organizations such as Mereo BioPharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mereo BioPharma within its industry.Mereo BioPharma Manpower Efficiency
Return on Mereo BioPharma Manpower
| Revenue Per Employee | 303K | |
| Revenue Per Executive | 833.3K | |
| Net Loss Per Employee | 892.9K | |
| Net Loss Per Executive | 2.5M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 4.5M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.